Development Status

The drugs and devices from our portfolio companies follow a clear development path from discovery to approval.

Current Therapeutics Development Status

Discovery

Pre-Ind

Ind

Phase 1

Phase 2

Phase 3

Lung Therapeutics LTI-01

75%

Lung Therapeutics LTI-02

30%

Lung Therapeutics LTI-03

30%

Azitra AZT-01

30%

Cognition Therapeutics CT-1812

55%

Encore Vision EV-06

75%

Lantern Pharma Tavocept

75%

Lantern Pharma Irofluven

75%

Lantern Pharma LP-184

30%

Actuate 9-ING-41

30%

Current Devices Development Status

Development

FDA Approval

Commercial

Abilitech’s Abilitech Exo

25%

410 Medical’s Lifeflow

85%

Current Therapeutics Development Status

Lung Therapeutics LTI-01 (Phase 2)

75%

Lung Therapeutics LTI-02 (Pre-IND)

30%

Lung Therapeutics LTI-03 (Pre-IND)

30%

Azitra AZT-01 (Pre-IND)

30%

Cognition Therapeutics CT-1812 (Phase 1)

55%

Encore Vision EV-06 (Phase 2)

75%

Lantern Pharma Tavocept (Phase 2)

75%

Lantern Pharma Irofluven (Phase 2)

75%

Lantern Pharma LP-184 (Pre-IND)

30%

Actuate 9-ING-41 (Pre-IND)

30%

Current Devices Development Status

Abilitech’s Abilitech Exo (Development)

25%

410 Medical’s Lifeflow (Commercial)

85%